Anthony Paproki
Queensland NIF Node Facility Fellow
Dr. Anthony Paproki completed a Master’s degree in Computer Science at the University of Technology of Belfort Montbéliard in 2011 and subsequently earned a PhD in Biomedical Imaging from the University of Queensland in 2016. His research focuses on developing advanced medical imaging algorithms, particularly for the automated segmentation and quantitative analysis of MRI data. During his PhD, Dr. Paproki developed deformable-model based algorithms for the segmentation and analysis of knee menisci in clinical and research MRI. His post-doctoral fellowship with the CSIRO furthered his expertise in medical image informatics, where he optimized MRI protocols for assessing lung disease in children with cystic fibrosis and ataxia-telangiectasia. He currently focuses on providing support for the development and application of AI for medical image analysis.
Related News
Network models brain changes in motor neurone disease to develop imaging tools for clinicians
Dr Sicong Tu is excited about helping motor neurone disease (MND) patients gain a much better idea of their disease progression: “The focus of our network is on bridging the gap between leading Aust
28 May 2025
New molecular-imaging network launched to benefit cancer, dementia imaging and new radiopharmaceuticals
A new national-scale molecular-imaging network that aims to improve cancer imaging, dementia diagnosis and treatment, and new radiopharmaceuticals was launched Saturday at the annual meeting for Austr
26 May 2025
Advance Queensland: AI-powered software to optimise brain stimulation therapy for major depression
NIF at Herston Imaging Research Facility is supporting the development of an AI-enabled device to enhance the effectiveness of transcranial magnetic stimulation (TMS) therapy for major depressive diso
18 February 2025
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
Long-term NIF user and collaborator, AdvanCell has secured $112m in Series C funding supported by Sanofi Ventures to advance its targeted alpha therapy for metastatic prostate cancer.
03 February 2025
Related Publications
In vivo biomarkers of GABAergic function in epileptic rats treated with the GAT-1 inhibitor E2730
Idrish Ali, Bianca Jupp, Matthew R. Hudson, Brendan Major, Juliana Silva, Glenn R. Yamakawa, Pablo M. Casillas-Espinosa, Emma Braine, Peravina Thergarajan, Mohammad B. Haskali, Lucy Vivash, Robert Brkljaca, Sandy R. Shultz, Patrick Kwan, Kazuyuki Fukushima, Pallavi Sachdev, Jocelyn Y. Cheng, Richelle Mychasiuk, Nigel C. Jones, David K. Wright, Terence J. OBrien
Read Publication
Functional conductivity imaging: quantitative mapping of brain activity
Jun Cao, Iain K. Ball, Benjamin Cassidy & Caroline D. Rae
Read Publication
Can an online battery match in-person cognitive testing in providing information about age-related cortical morphology?
R. Thienel, L. Borne, C. Faucher, A. Behler, G. A. Robinson, J. Fripp, J. Giorgio, A. Ceslis, K. McAloney, J. Adsett, D. Galligan, N. G. Martin, M. Breakspear & M. K. Lupton
Read Publication
Microstructural changes in the median and ulnar nerve in people with and without diabetic neuropathy in their hands: A cross-sectional diffusion MRI study
Eva Sierra-Silvestre, Robert E. Smith, Ricardo J. Andrade, Ben Kennedy, Michel W. Coppieters
Read Publication